PURPOSE: To evaluate the prognostic significance of CEBPA mutations in the context of established molecular markers in cytogenetically normal (CN) acute myeloid leukemia (AML) and gain biologic insights into leukemogenesis of the CN-AML molecular high-risk subset (FLT3 internal tandem duplication [ITD] positive and/or NPM1 wild type) that has a significantly higher incidence of CEBPA mutations than the molecular low-risk subset (FLT3-ITD negative and NPM1 mutated). PATIENTS AND METHODS: One hundred seventy-five adults age less than 60 years with untreated primary CN-AML were screened before treatment for CEBPA, FLT3, MLL, WT1, and NPM1 mutations and BAALC and ERG expression levels. Gene and microRNA (miRNA) expression profiles were obtained for the CN-AML molecular high-risk patients. RESULTS: CEBPA mutations predicted better event-free (P = .007), disease-free (P = .014), and overall survival (P < .001) independently of other molecular and clinical prognosticators. Among patients with CEBPA mutations, 91% were in the CN-AML molecular high-risk group. Within this group, CEBPA mutations predicted better event-free (P < .001), disease-free (P = .004), and overall survival (P = .009) independently of other molecular and clinical characteristics and were associated with unique gene and miRNA expression profiles. The major features of these profiles were upregulation of genes (eg, GATA1, ZFPM1, EPOR, and GFI1B) and miRNAs (ie, the miR-181 family) involved in erythroid differentiation and downregulation of homeobox genes. CONCLUSION: Pretreatment testing for CEBPA mutations identifies CN-AML patients with different outcomes, particularly in the molecular high-risk group, thus improving molecular risk-based classification of this large cytogenetic subset of AML. The gene and miRNA expression profiling provided insights into leukemogenesis of the CN-AML molecular high-risk group, indicating that CEBPA mutations are associated with partial erythroid differentiation.
PURPOSE: To evaluate the prognostic significance of CEBPA mutations in the context of established molecular markers in cytogenetically normal (CN) acute myeloid leukemia (AML) and gain biologic insights into leukemogenesis of the CN-AML molecular high-risk subset (FLT3 internal tandem duplication [ITD] positive and/or NPM1 wild type) that has a significantly higher incidence of CEBPA mutations than the molecular low-risk subset (FLT3-ITD negative and NPM1 mutated). PATIENTS AND METHODS: One hundred seventy-five adults age less than 60 years with untreated primary CN-AML were screened before treatment for CEBPA, FLT3, MLL, WT1, and NPM1 mutations and BAALC and ERG expression levels. Gene and microRNA (miRNA) expression profiles were obtained for the CN-AML molecular high-risk patients. RESULTS:CEBPA mutations predicted better event-free (P = .007), disease-free (P = .014), and overall survival (P < .001) independently of other molecular and clinical prognosticators. Among patients with CEBPA mutations, 91% were in the CN-AML molecular high-risk group. Within this group, CEBPA mutations predicted better event-free (P < .001), disease-free (P = .004), and overall survival (P = .009) independently of other molecular and clinical characteristics and were associated with unique gene and miRNA expression profiles. The major features of these profiles were upregulation of genes (eg, GATA1, ZFPM1, EPOR, and GFI1B) and miRNAs (ie, the miR-181 family) involved in erythroid differentiation and downregulation of homeobox genes. CONCLUSION: Pretreatment testing for CEBPA mutations identifies CN-AMLpatients with different outcomes, particularly in the molecular high-risk group, thus improving molecular risk-based classification of this large cytogenetic subset of AML. The gene and miRNA expression profiling provided insights into leukemogenesis of the CN-AML molecular high-risk group, indicating that CEBPA mutations are associated with partial erythroid differentiation.
Authors: Jörg Cammenga; James C Mulloy; Francisco J Berguido; Donal MacGrogan; Agnes Viale; Stephen D Nimer Journal: Blood Date: 2002-10-24 Impact factor: 22.113
Authors: Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: S P Whitman; K J Archer; L Feng; C Baldus; B Becknell; B D Carlson; A J Carroll; K Mrózek; J W Vardiman; S L George; J E Kolitz; R A Larson; C D Bloomfield; M A Caligiuri Journal: Cancer Res Date: 2001-10-01 Impact factor: 12.701
Authors: Adrian F Gombart; Wolf-K Hofmann; Seiji Kawano; Seisho Takeuchi; Utz Krug; Scott H Kwok; Renee J Larsen; Hiroya Asou; Carl W Miller; Dieter Hoelzer; H Phillip Koeffler Journal: Blood Date: 2002-02-15 Impact factor: 22.113
Authors: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Joost Meijer; Susanna van Oosterhoud; Wim L J van Putten; Peter J M Valk; H Berna Beverloo; Daniel G Tenen; Bob Löwenberg; Ruud Delwel Journal: Hematol J Date: 2003
Authors: John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: Zejuan Li; Hao Huang; Yuanyuan Li; Xi Jiang; Ping Chen; Stephen Arnovitz; Michael D Radmacher; Kati Maharry; Abdel Elkahloun; Xinan Yang; Chunjiang He; Miao He; Zhiyu Zhang; Konstanze Dohner; Mary Beth Neilly; Colles Price; Yves A Lussier; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Lars Bullinger; Peter J M Valk; Ruud Delwel; Bob Lowenberg; Paul P Liu; Guido Marcucci; Clara D Bloomfield; Janet D Rowley; Jianjun Chen Journal: Blood Date: 2012-01-17 Impact factor: 22.113
Authors: Thomas Ernst; Andrew Chase; Katerina Zoi; Katherine Waghorn; Claire Hidalgo-Curtis; Joannah Score; Amy Jones; Francis Grand; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross Journal: Haematologica Date: 2010-04-26 Impact factor: 9.941
Authors: Sebastian Schwind; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Susan P Whitman; Christopher Hickey; Heiko Becker; Klaus H Metzeler; Peter Paschka; Claudia D Baldus; Shujun Liu; Ramiro Garzon; Bayard L Powell; Jonathan E Kolitz; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Guido Marcucci; Clara D Bloomfield Journal: J Clin Oncol Date: 2010-11-15 Impact factor: 44.544
Authors: Zejuan Li; Tobias Herold; Chunjiang He; Peter J M Valk; Ping Chen; Vindi Jurinovic; Ulrich Mansmann; Michael D Radmacher; Kati S Maharry; Miao Sun; Xinan Yang; Hao Huang; Xi Jiang; Maria-Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann; Abdel Elkahloun; Mary Beth Neilly; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Konstanze Döhner; Lars Bullinger; Paul P Liu; Ruud Delwel; Guido Marcucci; Bob Lowenberg; Clara D Bloomfield; Janet D Rowley; Stefan K Bohlander; Jianjun Chen Journal: J Clin Oncol Date: 2013-02-04 Impact factor: 44.544
Authors: Christopher J Walker; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Krzysztof Mrózek; Sandya Liyanarachchi; Chi Song; Deedra Nicolet; James S Blachly; Marius Bill; Dimitrios Papaioannou; Christopher C Oakes; Brian Giacopelli; Luke K Genutis; Sophia E Maharry; Shelley Orwick; Kellie J Archer; Bayard L Powell; Jonathan E Kolitz; Geoffrey L Uy; Eunice S Wang; Andrew J Carroll; Richard M Stone; John C Byrd; Albert de la Chapelle; Clara D Bloomfield Journal: Clin Cancer Res Date: 2019-08-02 Impact factor: 12.531